Diagnosis of Overactive Bladder
- 394 Downloads
Overactive bladder (OAB) is a highly prevalent disorder impacting millions of people’s lives throughout the world. Our goal in this chapter is to define the condition as it has evolved over the past few decades. We will then review the basis for establishing a diagnosis, which includes a thorough symptom assessment as well as physical exam and urine studies. The use of adjunctive tests will also be reviewed, although their utility is limited in the diagnosis of an index patient with OAB.
KeywordsOAB diagnosis OAB prevalence Urodynamics Voiding diary
- 5.Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol. 1988;114(Suppl):5–19.Google Scholar
- 11.Freeman R, Hill S, Millard R, Slack M, Sutherst J; Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol. 2003;102(3):605–11.Google Scholar
- 14.Rovner ES, Wein AJ. Today’s treatment of overactive bladder and urge incontinence. Women’s Health in Prim Care. 2000;3(3):179–92.Google Scholar
- 16.Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. 2012; amended 2014. http://www.auanet.org/guidelines/overactive-bladder-(oab)-(aua/sufu-guideline-2012-amended-2014. Accessed 27 Apr 2018.
- 18.National Institute of Clinical Excellence (NICE). CG171 urinary incontinence in women: full guideline. 2013.Google Scholar
- 27.Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001;76(4):358–63.CrossRefGoogle Scholar
- 30.Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–95.CrossRefGoogle Scholar
- 37.Homma Y, Batista JE, Bauer SB, Griffiths DJ, Hilton P, Kramer G, et al. Urodynamics. In: Abrams P, Wein A, Schussler B, Kawabi K, Bump R, Melchior H, et al., editors. Incontinence. First international consultation on incontinence. Recommendations of the International Scientific Committee: the evaluation and treatment of urinary incontinence. Plymouth: Health Publication Ltd; 1999. p. 317–72.Google Scholar
- 38.Masunaga K, Yoshida M, Inadome A, Iwashita H, Miyamae K, Ueda S. Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. In J Urol. 2006;13(3):271–6.Google Scholar